OINDPnews


Aptar Pharma banner

Business

Iconovo announces deal with Respiratorius for development of DPI

Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3 million, the company said. The project, which involves development of Respiratorius's RES030-085 for the treatment of COPD and severe asthma, would lead to a license agreement if … [Read more...] about Iconovo announces deal with Respiratorius for development of DPI

Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST

Milestone Pharmaceuticals has announced a new agreement with Ji Xing Pharmaceuticals giving Ji Xing Chinese development and commercialization rights to Milestone's etripamil nasal spray in patients with cardiovascular conditions, including paroxysmal supraventricular tachycardia (PSVT). Ji Xing will pay $15 million up front and up to $107.5 million in milestone and … [Read more...] about Ji Xing Pharmaceuticals gets Chinese rights to etripamil for PVST

Akroswiss gets funding for development of midazolam nasal spray

Swiss start-up Akroswiss has announced that it raised "several million Swiss Franc" for development of the company's midazolam nasal spray for the prevention of claustrophobia and for the rescue treatment of epileptic seizures. Investors include Linsi, Bernhard Schuknecht, and Walter P. Hölzle, who is also the company's Head of Business Development. According to the … [Read more...] about Akroswiss gets funding for development of midazolam nasal spray

Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division

DPI developer Iconovo has announced that its development deal with Amneal for a generic version of Symbicort has been amended to add US and Chinese marketing rights for Amneal and Nordic region marketing rights for Iconovo. Acquisition of the Nordic marketing rights also marks the launch of a new division of Iconovo, Iconovo Pharma. The original deal included … [Read more...] about Iconovo announces expansion of deal with Amneal on generic Symbicort and launch of pharma division

Pulmatrix says Cipla has breached a 2019 development agreement for Pulmazole intraconazole DPI

A month after regaining rights to PUR1800 and other inhaled narrow spectrum kinase inhibitors from Johnson & Johnson, Pulmatrix has announced that it may also reacquire the rights to its Pulmazole intraconazole DPI (PUR 1900). According to the company's business update, Pulmatrix recently notified Cipla that Cipla breached a 2019 development and commercialization … [Read more...] about Pulmatrix says Cipla has breached a 2019 development agreement for Pulmazole intraconazole DPI

Vectura to develop inhaled formulation of Inspira candidate for the treatment of COVID-19

Inhalation CDMO Vectura has signed an agreement with Inspira Pharmaceuticals to develop an inhaled formulation of a plant extract Inspira is developing for the treatment of COVID-19, the company said. Vectura will create a version of the IPX formulation to be delivered via Vectura's Fox vibrating mesh nebulizer for Phase 1 trials. Inspira is looking to raise £350,000 … [Read more...] about Vectura to develop inhaled formulation of Inspira candidate for the treatment of COVID-19

Hikma re-starts launch of its generic version of Advair Diskus

Hikma Pharmaceuticals said that the FDA has approved an amendment to the company's ANDA for its generic version of Advair Diskus fluticasone propionate / salmeterol DPI, and the company has subsequently restarted the launch of the inhaler. The FDA initially approved the ANDA in December 2020, and the company said that it was launching the DPI at that time. Hikma … [Read more...] about Hikma re-starts launch of its generic version of Advair Diskus

NeuroRx and Relief Therapeutics publicly air disputes over Zyesami collaboration agreement

NeuroRx and Relief Therapeutics have each issued press releases enumerating disagreements between the companies regarding development of Zyesami aviptadil (RLF-100), a synthetic vasoactive intestinal peptide. The two companies are partnered on development of the formulation for the treatment of acute respiratory distress syndrome caused by COVID-19, for both … [Read more...] about NeuroRx and Relief Therapeutics publicly air disputes over Zyesami collaboration agreement

Virpax says MMS019 nasal spray inhibits viral replication in pre-clinical study

Virpax Pharmaceuticals announced that a study of its MMS019 powder "masking spray" in mice demonstrated "a marked inhibition of viral replication in the mouse nasal passages" for mice infected with SARS-CoV-2 and then given MMS019 intranasally for 6 days. Virpax licensed MMS019 from Nanomerics in August 2020 and is developing the formulation for the prevention of … [Read more...] about Virpax says MMS019 nasal spray inhibits viral replication in pre-clinical study